SEC INSIDER TRANSACTIONS

Moderna, Inc. (MRNA) Insider Transactions

Explore official ownership filings, with every record linked to its source.

Reported data · not live

MRNA · Moderna, Inc.

Filing window SEC codes (comma separated) Security type Order

More transaction filters

Roles: director,officer,ten_percent_owner,otherOwner nameOfficer titleOwnership: D, I, unknownoriginal or amendedTransaction fromTransaction throughFiled fromFiled throughMinimum quantityMaximum quantityMinimum priceMaximum priceMinimum calculated valueMaximum calculated valueResults per page (1–100)

OR within codes/roles; AND between categories. Roles apply to buyers and sellers. Owner predicates match the same owner. Missing values fail numeric/date filters. Value is quantity × reported price for non-derivative rows only; derivative values are unknown. Amendments stay separate; joint owners do not duplicate rows.

Reset filters

Active filters: days=6m

Stale snapshot · Covered: filings 2026-05-14 to 2026-11-13 · 32 filings · fetched 2026-11-13T18:57:57Z

Recent reported activity

0purchase rows on this page

7sale rows on this page

130matching filing rows

Purchases and sales count original non-derivative P and S rows. Awards, gifts, exercises, derivatives and amendments are shown separately and are not described as market purchases.

Transaction / filed	Reporting owner(s)	Code / security	Quantity	Price as filed	Ownership	Source
2026-11-05Filed 2026-11-09	Andres JuanOfficer · Chief Operating Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 25% of this option will vest and become exercisable on November 5, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F2 Restricted stock units convert into common stock on a one-for-one basis. F3 25% of the shares subject to this restricted stock unit award will vest on November 5, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter. References: F2, F3	A Award / grantRestricted Stock Units · Derivative	16,955A	0	Direct	Form 4 ↗0001682852-26-000199
2026-11-05Filed 2026-11-09	Andres JuanOfficer · Chief Operating Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 25% of this option will vest and become exercisable on November 5, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F2 Restricted stock units convert into common stock on a one-for-one basis. F3 25% of the shares subject to this restricted stock unit award will vest on November 5, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter. References: F1	A Award / grantStock Option (Right to Buy) · Derivative	7,898A	0	Direct	Form 4 ↗0001682852-26-000199
2026-10-15Filed 2026-10-16	Hoge StephenOfficer · President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $213.03 to $213.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $214.05 to $214.37. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $220.60 to $221.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5 These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. F6 This option is fully vested and exercisable. References: F1, F6	M Exercise / conversionStock Option (Right to Buy) · Derivative	76,452D	0	Direct	Form 4 ↗0001682852-26-000187
2026-10-15Filed 2026-10-16	Hoge StephenOfficer · President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $213.03 to $213.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $214.05 to $214.37. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $220.60 to $221.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5 These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. F6 This option is fully vested and exercisable. References: F1, F4	S Sale (market/private)Common Stock · Non-derivative	39,145D	220.72	Direct	Form 4 ↗0001682852-26-000187
2026-10-15Filed 2026-10-16	Hoge StephenOfficer · President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $213.03 to $213.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $214.05 to $214.37. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $220.60 to $221.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5 These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. F6 This option is fully vested and exercisable. References: F1	M Exercise / conversionCommon Stock · Non-derivative	76,452A	12.21	Direct	Form 4 ↗0001682852-26-000187
2026-10-14Filed 2026-10-16	Hoge StephenOfficer · President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $213.03 to $213.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $214.05 to $214.37. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $220.60 to $221.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5 These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. F6 This option is fully vested and exercisable. References: F1, F6	M Exercise / conversionStock Option (Right to Buy) · Derivative	76,453D	0	Direct	Form 4 ↗0001682852-26-000187
2026-10-14Filed 2026-10-16	Hoge StephenOfficer · President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $213.03 to $213.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $214.05 to $214.37. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $220.60 to $221.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5 These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. F6 This option is fully vested and exercisable. References: F1, F3	S Sale (market/private)Common Stock · Non-derivative	450D	214.15	Direct	Form 4 ↗0001682852-26-000187
2026-10-14Filed 2026-10-16	Hoge StephenOfficer · President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $213.03 to $213.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $214.05 to $214.37. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $220.60 to $221.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5 These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. F6 This option is fully vested and exercisable. References: F1, F2	S Sale (market/private)Common Stock · Non-derivative	38,774D	213.47	Direct	Form 4 ↗0001682852-26-000187
2026-10-14Filed 2026-10-16	Hoge StephenOfficer · President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $213.03 to $213.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $214.05 to $214.37. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $220.60 to $221.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5 These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. F6 This option is fully vested and exercisable. References: F1	M Exercise / conversionCommon Stock · Non-derivative	76,453A	12.21	Direct	Form 4 ↗0001682852-26-000187
2026-10-05Filed 2026-10-07	Mock James MOfficer · Chief Financial Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Restricted stock units convert into common stock on a one-for-one basis. F2 Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. F3 25% of the shares subject to this restricted stock unit award vested on October 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. References: F1, F3	M Exercise / conversionRestricted Stock Units · Derivative	1,454D	0	Direct	Form 4 ↗0001682852-26-000185
2026-10-05Filed 2026-10-07	Mock James MOfficer · Chief Financial Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Restricted stock units convert into common stock on a one-for-one basis. F2 Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. F3 25% of the shares subject to this restricted stock unit award vested on October 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. References: F2	F WithholdingCommon Stock · Non-derivative	704D	190.01	Direct	Form 4 ↗0001682852-26-000185
2026-10-05Filed 2026-10-07	Mock James MOfficer · Chief Financial Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Restricted stock units convert into common stock on a one-for-one basis. F2 Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. F3 25% of the shares subject to this restricted stock unit award vested on October 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. References: F1	M Exercise / conversionCommon Stock · Non-derivative	1,454A	—	Direct	Form 4 ↗0001682852-26-000185
2026-09-15Filed 2026-09-16	Hoge StephenOfficer · President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $143.99 to $144.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $145.97 to $146.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F4 These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. F5 This option is fully vested and exercisable. References: F1, F5	M Exercise / conversionStock Option (Right to Buy) · Derivative	76,452D	0	Direct	Form 4 ↗0001682852-26-000176
2026-09-15Filed 2026-09-16	Hoge StephenOfficer · President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $143.99 to $144.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $145.97 to $146.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F4 These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. F5 This option is fully vested and exercisable. References: F1, F3	S Sale (market/private)Common Stock · Non-derivative	40,281D	146.07	Direct	Form 4 ↗0001682852-26-000176
2026-09-15Filed 2026-09-16	Hoge StephenOfficer · President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $143.99 to $144.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $145.97 to $146.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F4 These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. F5 This option is fully vested and exercisable. References: F1	M Exercise / conversionCommon Stock · Non-derivative	76,452A	12.21	Direct	Form 4 ↗0001682852-26-000176
2026-09-14Filed 2026-09-16	Hoge StephenOfficer · President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $143.99 to $144.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $145.97 to $146.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F4 These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. F5 This option is fully vested and exercisable. References: F1, F5	M Exercise / conversionStock Option (Right to Buy) · Derivative	76,453D	0	Direct	Form 4 ↗0001682852-26-000176
2026-09-14Filed 2026-09-16	Hoge StephenOfficer · President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $143.99 to $144.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $145.97 to $146.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F4 These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. F5 This option is fully vested and exercisable. References: F1, F2	S Sale (market/private)Common Stock · Non-derivative	40,294D	144.13	Direct	Form 4 ↗0001682852-26-000176
2026-09-14Filed 2026-09-16	Hoge StephenOfficer · President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $143.99 to $144.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $145.97 to $146.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F4 These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. F5 This option is fully vested and exercisable. References: F1	M Exercise / conversionCommon Stock · Non-derivative	76,453A	12.21	Direct	Form 4 ↗0001682852-26-000176
2026-09-10Filed 2026-09-14	Mock James MOfficer · Chief Financial Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2026. F2 25% of this option vested and become exercisable on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter. References: F1, F2	M Exercise / conversionStock Option (Right to Buy) · Derivative	19,836D	0	Direct	Form 4 ↗0001682852-26-000174
2026-09-10Filed 2026-09-14	Mock James MOfficer · Chief Financial Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2026. F2 25% of this option vested and become exercisable on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter. References: F1	S Sale (market/private)Common Stock · Non-derivative	15,000D	134.49	Direct	Form 4 ↗0001682852-26-000174
2026-09-10Filed 2026-09-14	Mock James MOfficer · Chief Financial Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2026. F2 25% of this option vested and become exercisable on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter. References: F1	S Sale (market/private)Common Stock · Non-derivative	19,836D	134.49	Direct	Form 4 ↗0001682852-26-000174
2026-09-10Filed 2026-09-14	Mock James MOfficer · Chief Financial Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2026. F2 25% of this option vested and become exercisable on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter. References: F1	M Exercise / conversionCommon Stock · Non-derivative	19,836A	30.96	Direct	Form 4 ↗0001682852-26-000174
2026-09-04Filed 2026-09-08	Mock James MOfficer · Chief Financial Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Restricted stock units convert into common stock on a one-for-one basis. F2 Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. F3 25% of the shares subject to this restricted stock unit award vested on December 5, 2025, with the remainder vesting in twelve (12) equal quarterly installments thereafter. References: F1, F3	M Exercise / conversionRestricted Stock Units · Derivative	11,797D	0	Direct	Form 4 ↗0001682852-26-000172
2026-09-04Filed 2026-09-08	Mock James MOfficer · Chief Financial Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Restricted stock units convert into common stock on a one-for-one basis. F2 Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. F3 25% of the shares subject to this restricted stock unit award vested on December 5, 2025, with the remainder vesting in twelve (12) equal quarterly installments thereafter. References: F2	F WithholdingCommon Stock · Non-derivative	5,704D	148.87	Direct	Form 4 ↗0001682852-26-000172
2026-09-04Filed 2026-09-08	Mock James MOfficer · Chief Financial Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Restricted stock units convert into common stock on a one-for-one basis. F2 Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. F3 25% of the shares subject to this restricted stock unit award vested on December 5, 2025, with the remainder vesting in twelve (12) equal quarterly installments thereafter. References: F1	M Exercise / conversionCommon Stock · Non-derivative	11,797A	—	Direct	Form 4 ↗0001682852-26-000172

Imported instruments only. Joint owners do not multiply transactions. Amendments are separate filing rows, not additional trades. No aggregate trade totals are implied.